222 related articles for article (PubMed ID: 35339648)
21. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
22. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Correale P; Saladino RE; Giannarelli D; Giannicola R; Agostino R; Staropoli N; Strangio A; Del Giudice T; Nardone V; Altomonte M; Pastina P; Tini P; Falzea AC; Imbesi N; Arcati V; Romeo G; Caracciolo D; Luce A; Caraglia M; Giordano A; Pirtoli L; Necas A; Amler E; Barbieri V; Tassone P; Tagliaferri P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554614
[TBL] [Abstract][Full Text] [Related]
23. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
24. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
[TBL] [Abstract][Full Text] [Related]
25. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
26. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
27. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C; Cassier P; Zamarin D; Machiels JP; Perez Gracia JL; Stephen Hodi F; Taus A; Martinez Garcia M; Boni V; Eder JP; Hafez N; Sullivan R; Mcdermott D; Champiat S; Aspeslagh S; Terret C; Jegg AM; Jacob W; Cannarile MA; Ries C; Korski K; Michielin F; Christen R; Babitzki G; Watson C; Meneses-Lorente G; Weisser M; Rüttinger D; Delord JP; Marabelle A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577503
[TBL] [Abstract][Full Text] [Related]
28. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
[TBL] [Abstract][Full Text] [Related]
29. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
30. bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer.
Fan Y; Liu Y; Wang L; Cai Y; Cao W; Sun W; Zou X; Li B; Zhang Z; Cai S; Chuai S; Han Y; Pan X; Huang D
EBioMedicine; 2023 May; 91():104564. PubMed ID: 37094467
[TBL] [Abstract][Full Text] [Related]
31. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
32. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
McGranahan N; Furness AJ; Rosenthal R; Ramskov S; Lyngaa R; Saini SK; Jamal-Hanjani M; Wilson GA; Birkbak NJ; Hiley CT; Watkins TB; Shafi S; Murugaesu N; Mitter R; Akarca AU; Linares J; Marafioti T; Henry JY; Van Allen EM; Miao D; Schilling B; Schadendorf D; Garraway LA; Makarov V; Rizvi NA; Snyder A; Hellmann MD; Merghoub T; Wolchok JD; Shukla SA; Wu CJ; Peggs KS; Chan TA; Hadrup SR; Quezada SA; Swanton C
Science; 2016 Mar; 351(6280):1463-9. PubMed ID: 26940869
[TBL] [Abstract][Full Text] [Related]
33. Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.
Cummings AL; Gukasyan J; Lu HY; Grogan T; Sunga G; Fares CM; Hornstein N; Zaretsky J; Carroll J; Bachrach B; Akingbemi WO; Li D; Noor Z; Lisberg A; Goldman JW; Elashoff D; Bui AAT; Ribas A; Dubinett SM; Rossetti M; Garon EB
Nat Cancer; 2020 Dec; 1(12):1167-1175. PubMed ID: 35121931
[TBL] [Abstract][Full Text] [Related]
34. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Tian Y; Zhai X; Yan W; Zhu H; Yu J
Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
[TBL] [Abstract][Full Text] [Related]
36. Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.
Yang Y; Kim E; Kim S
Genes Genomics; 2022 Apr; 44(4):509-515. PubMed ID: 35107815
[TBL] [Abstract][Full Text] [Related]
37.
Ibáñez-Molero S; van Vliet A; Pozniak J; Hummelink K; Terry AM; Monkhorst K; Sanders J; Hofland I; Landeloos E; Van Herck Y; Bechter O; Kuilman T; Zhong W; Marine JC; Wessels L; Peeper DS
Oncoimmunology; 2022; 11(1):2139074. PubMed ID: 36465485
[TBL] [Abstract][Full Text] [Related]
38. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
39. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
40. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
